INTRODUCTION INTRODUCTION
the treatment of extensive psoriasis. Unfortunately, the risk of hepatic fibrosis and cirrhosis has precluded the Niosomes or non-ionic surfactant vesicles are now widely use of this drug in the great majority of patients with studied as an alternative to liposomes. An increasing number localized psoriasis. To avoid systemic toxicity, topical of non-ionic surfactants have been found to form vesicles, administration of methotrexate was attempted. Stewart et al capable of entrapping hydrophobic and hydrophilic solutes.
and McCullough et al suggested that localized methotrexate These novel drug deliveries have been used in the preparation of various drugs to enhance the penetration and also to sustain the release of the drug. [1, 2] The currently available topical treatments for psoriasis that have been found to be effective include coal tar, anthralin calcipotriol, corticosteroids, photochemotherapy, retinoids, methotrexate, urea etc. [3] Methotrexate is an effective systemic cytotoxic drug for did not yield much penetration to produce significant clinical effect in psoriasis. [4, 5] We tried a new approach for topical delivery of methotrexate by niosomal encapsulation that was aimed at increased percutaneous penetration and therapeutic effectiveness.
METHODS METHODS
The phase I and phase II study, was conducted at Victoria Lakshmi PK, et al.: Niosomal methotrexate gel in treatment of psoriasis clearance was obtained to conduct the trial on human volunteers and patients.
Preparation of test materials
The test materials used were niosomal methotrexate (0.25%) gel (CH1NMTX2), marketed methotrexate (0.25%) gel (MTX) and the placebo gel (control).
The lipid layer hydration method was followed with slight modifications. The niosomes formed were characterized for particle size, zeta potential, stability interaction with niosomal methotrexate 0.25% incorporated chitosan gel to excipients and in vitro release studies. The characterized treat patients affected with localized psoriasis of less than niosomes were incorporated in chitosan gel. Chitosan-I 25% of body surface area involvement. All the participating (mol. wt -5.47x 10 5 D) and Chitosan-II (mol. wt -8.82 x patients gave their informed consent before joining the study. D) were used in 2:1 proportion for the preparation Thirty patients were randomized into three groups using of the gel. The gel was prepared by incorporating 0.25% computer-generated random numbers. equivalent of niosomal methotrexate in glycerin and propylene glycol. [6] [7] [8] Adult patients of both sexes, suffering from stable psoriasis involving < 25% of the body surface area were included in The pH of the marketed gel (Rextop © , Systopic India the study. Pregnant and or lactating women and children Limited TM ) was found to be 5.2 with viscosity of 7850 cps. were excluded. A washout period of two weeks for topical The viscosity and pH of niosomal methotrexate was 8600 cps therapy and two months for systemic or ultraviolet therapy and 5.0-5.2 respectively. was observed. Patients with lesions on face or scalp alone were excluded. Alcoholic patients and those with The placebo, niosomal methotrexate gel and marketed concomitant renal, hepatic and hematological abnormalities gel were tested for repeated insult patch test (RIPT) on were excluded. human volunteers to assess the irritation potential of the methotrexate gel on the skin. This was followed by a doubleEach patient underwent physical examination and standard blind placebo-controlled study in patients of psoriasis to laboratory tests such as complete hemogram, renal function, assess the efficacy. The permission to conduct a study was serum creatinine, blood urea nitrogen and liver function obtained from the institutional ethical committee (IEC).
tests.
Phase I study: RIPT [9, 10] Patients were randomly allocated to three different groups. The RIPT is a standard method to detect a product's propensity Study included twice daily application of 10 g gel over to produce contact dermatitis. All the participating volunteers psoriatic lesions for five consecutive days per week except gave their informed consent before joining the study. Four niosomal methotrexate which was applied once daily in the female and six male healthy human volunteers with mean age morning. Placebo gel was applied in the night. Patients were site for the next application. If a Level 2 or greater reaction occurred on the new site, no further induction applications were made. The human volunteers were given two weeks washout period and proceeded with the next formulation for RIPT.
Phase II study: Double-blind placebo-controlled study [11, 12] The purpose of this placebo-controlled double-blind study was to evaluate the clinical efficacy and tolerability of 10 5 of 35.5 ± 2.5 and 44 ± 1.5 respectively were selected for the study after the standard inclusion and exclusion criteria for RIPT were satisfied. The test was conducted in two phases, induction and challenge phase as per accepted protocol for such tests. [9, 10] A small quantity of gel (0.2 g) was applied to the aluminum Finn chambers. The occlusive dressing used for covering the skin was ¾" x ¾" absorbent pad center of a non-porous adhesive dressing. The application area was scored on a 0-5 point scale as described by previous workers. [9, 10] In case a subject developed a Level 2 reaction or greater during the induction phase, the patch was applied to an adjacent fresh asked to apply not more than 0.5 g/day.
Drug-related side-effects reported by the patient were recorded by directly questioning the subjects. The efficacy of the treatment was evaluated at the end of every two weeks. The study was concluded at the end of 12 weeks.
The severity of the lesions of psoriasis was evaluated using Psoriasis Area Severity Index (PASI) described by Sutton et al and Frediksson et al. [11, 12] Global assessment was made by the physician to assess the outcome of therapy (on a scale of 0 5). [11] A score of 5 indicates the worsening of lesion and score 0 indicates complete clearance of lesion.
( w w w
Lakshmi PK, et al.: Niosomal methotrexate gel in treatment of psoriasis
Statistical analysis
One-way ANOVA test was used to compare the relationship between the outcome and treatment with the help of Instat © statistical software. Tukey's HSD test was used for post-hoc analysis. Variables such as age, sex and presence of plaque psoriasis and duration of the disease were examined to rule out differences between the control and the test formulations.
RESULT TS RESUL
There was no difference in reduction of desquamation scores at week 2. However, from week 4 onwards there was a significant difference (P<0.001) in the reduction of desquamation scores between placebo and the niosomal formulation.
At baseline there was no significant difference in the PASI score between groups but from week 4 a significant difference (P<0.05) was seen between the placebo and the two active formulations. At week 6 and 8 there was a significant difference The double-blind placebo-controlled study involved the assessment of efficacy of the test formulations on psoriasis. Full patient compliance was achieved with the study medication. The control and trial preparations were well tolerated by all the patients and there were no dropouts. All 30 patients were available for efficacy analysis. Demographically, control and test formulation groups were comparable in age, sex and the duration of the disease [ Table 1 ]. All patients completed the 12 weeks of active treatment.
The erythema scores suggest that there was no significant difference between the three groups at baseline. At the end of the second week both the active formulations showed significantly reduced erythema (P< 0.05) as compared to placebo. From Week 6 there was significant (P< 0.001) difference seen in the reduction of erythema by both the active formulations in comparison to placebo and also at that time, niosomal methotrexate was significantly better than the marketed formulation of methotrexate.
The infiltration scores at baseline were comparable in all three groups. Tukey's test shows that the niosomal formulations were significantly different in reducing the infiltration scores compared to placebo and the marketed formulation. The niosomal formulation showed significant (P<0.001) difference from week 2 to week 12 suggesting that it was more efficacious than the placebo and the marketed formulation.
in reduction of PASI (P<0.05) with all the active formulations [ Figure 1 ]. At week 12, with niosomal methotrexate gel there was highly significant (P<0.001) reduction in total score from 6.7378±1.48576 to 2.0023±1.13718. These results suggested that niosomal methotrexate gel was more efficacious than placebo, marketed gel. From Week 4 to Week 12 there was a significant difference (P< 0.001) in global score between the formulations [ Figure 2 ].
At the end of the study laboratory tests including complete blood count with differential and platelet count, renal function, serum creatinine, blood urea nitrogen and liver function test were found to be within normal limits. Patients experienced no drug-related adverse symptoms, either local or systemic.
The desquamation scores at baseline suggested that there was no significant difference between the formulations. 
DISCUSSION DISCUSSION
Systemic administration of methotrexate is known for its toxicity; hence the need for a topical preparation. Although earlier preparations of topical methotrexate were found to be not as efficacious, [4, 5] there is substantial evidence to support the pharmacological action of methotrexate in psoriasis. Methotrexate selectively inhibits de novo DNA synthesis, blocks mitosis and lethally damages cells in psoriatic epidermis when administered both systemically and locally
The current study comparing two formulations with placebo gel did not produce any significant irritation or sensitization on human volunteers as indicated by negative RIPT and these formulations were therefore later tested clinically on the psoriasis patients.
Though 20% patients treated with CH1NMTX2 and 40% patients treated with MMTX did not show much improvement, niosomal methotrexate 0.25% gel significantly improved psoriasis without inducing any allied side-effects. In comparison with by intradermal injection.
the placebo and the marketed gel, results with niosomal preparation were much better in terms of clinical efficacy, Studies done on methotrexate topical formulation in tolerability and patient compliance. propylene glycol base, twice-daily application reported adequate percutaneous penetration and beneficial effect in
The results show that topical methotrexate can treat psoriasis palmoplantar psoriasis. Topical methotrexate in hydrophilic and niosomal methotrexate gel has better absorption and gel (hydroxy ethyl cellulose 1%) has been prepared and used penetration of methotrexate through the skin. Once daily in the treatment of psoriasis vulgaris. [13, 14] These studies application of niosomal methotrexate gel may improve the concluded that methotrexate (0.25%) in a hydrophilic gel compliance of psoriatic patients. was clinically more effective, tolerable and beneficial in enhancing resolution of psoriasis vulgaris as compared to
Though the results were encouraging, Phase II study was a placebo. [13, 14] done on only 10 patients with each formulation in a single center. More number of patients with a multicentric study We attempted to reduce the systemic toxicity of methotrexate needs to be conducted to conclude about the efficacy of the by encapsulating it in niosomes and providing the drug new formulation. delivery through topical application. No single mechanism explains the efficacy of niosomes. Topically applied niosomes A ACKNOWLEDGMEN CKNOWLEDGMENT can increase the residence time of drugs in the stratum corneum (SC) and epidermis, while reducing the systemic We extend our thanks to Dabur India Limited and Fisheries absorption of the drug. They are thought to improve the department, Kerala for providing methotrexate USP, Spans horny layer properties, both by reducing trans-epidermal and chitosan. water loss and by increasing smoothness via replenishing lost skin lipids. The niosome vesicles form a lipid film on REFERENCES REFERENCES the skin, which can retain water, causing an improvement of SC intra-and intercellular hydration. Therefore, the compact 1. Yoshioka T, Brigitte Sternberg, Alexander T. Florence. structure of the SC is opened and the barrier permeability Preparation and properties of vesicles (niosomes) of sorbitan is increased. [2, 15] monoesters (Span 20, 40, 60 and 80) and sorbitan triester (Span For niosomal encapsulation, lipid layer hydration method with pH 5-phosphate buffer was used. The acid dissociation constant (pKa) of methotrexate is 5. At pH 5, methotrexate exists in unionized form. Topical application on the skin involves passive transport of drug and better transport was observed when in unionized form. Hence methotrexate in pH 5 buffer was used in the preparation of niosomes. The gels were prepared with chitosan. It provides absorption-promoting effect probably by improved adhesion between the formulation and the tissues, but also due to transient effect of chitosan on paracellular transport processes. ) .
